This week on CLL Society (cllsociety.org) in our 2015 conference coverage (cllsociety.org/conference-c... section, we feature an interview with me by fellow CLL patient, Carol Preston of Patient Power (patientpower.info) where I quickly outline my take on three papers from ASCO 2015 on CLL.
ASCO is more about solid cancers, so the news on CLL tends to be scarce.
The three presentations are on a new prognostic scale, on a new non-chemo triplet therapy and finally on Bendamustine with and without ibrutinib.
In the accompanying text, I go into more detail, and of course provide a link to the source material itself so we can all form our own opinions.
Your comments are welcome.
I am off to iwCLL 2015 in a few weeks where I will be speaking on a panel with Dr. Keating and others on how to improve access to expensive cancer medications. I also plan to meet other CLL patients and interview the experts gathered in Sydney, Australia.
The iWCLL is going ahead, but the planned Patient Education Day was unfortunately cancelled much to our disappointment. There is now no associated patient events other than a Q&A session with one or more visiting CLL experts that Brian and Lymphoma Australia are arranging. I don't know yet the details of that, though perhaps Brian has some more news?
We had also planned to have a session led by Brian at the end of the day for those interested in setting up a CLL Patient Advocacy Group for Australians and I'm still collecting names of people interested in supporting this. Are you interested?
The meeting will be at the same time and likely at the same hotel, just in a smaller room and of shorter duration. Lymphoma AU is working on the details.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
